Back

Orvida Pharma secures Recordati-led financing as Olmsted syndrome data target fourth quarter 2026

Verifying
  • Orvida Pharma completed interim financing led by Recordati with participation from existing shareholders.
  • Phase 1b topline results are expected in the fourth quarter of 2026.
  • Orvida initiated the Olmsted syndrome trial in Europe and the U.S.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.